目的 探讨槐杞黄颗粒联合重组人血小板生成素治疗特发性血小板减少性紫癜的临床疗效。方法 选取2017年1月-2018年2月青岛市市立医院（集团）收治的特发性血小板减少性紫癜患者84例为研究对象，按照随机数字表法分为对照组和治疗组，每组各42例。对照组皮下注射重组人血小板生成素注射液，15 000 U/次，1次/d。治疗组在对照组基础上温水冲服槐杞黄颗粒，1袋/次，2次/d。两组连续治疗14 d。观察两组的临床疗效，比较两组的血小板相关抗体、血小板计数、T淋巴细胞亚群。结果 治疗后，对照组和治疗组的总有效率分别为73.81%、90.48%，两组比较差异有统计学意义（P<0.05）。治疗后，两组血小板相关免疫球蛋白G（PAIgG）、血小板相关免疫球蛋白A（PAIgA）、血小板相关免疫球蛋白M（PAIgM）水平明显降低，而血小板计数明显升高，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标明显优于对照组，两组比较差异具有统计学意义（P<0.05）。治疗后，两组CD3⁺、CD4⁺、CD4⁺/CD8⁺水平明显升高，而CD8⁺水平明显降低，同组治疗前后比较差异有统计学意义（P<0.05）；且治疗组这些观察指标明显优于对照组，两组比较差异具有统计学意义（P<0.05）。结论 槐杞黄颗粒联合重组人血小板生成素治疗特发性血小板减少性紫癜具有较好的临床疗效，能降低血小板相关抗体，改善机体免疫功能，降低不良反应的发生，具有一定的临床推广应用价值。

Objective To observe the clinical efficacy of Huaiqihuang Granules combined with recombinant human thrombopoietin in treatment of idiopathic thrombocytopenic purpura. Methods Patients (84 cases) with idiopathic thrombocytopenic purpura in Qingdao Municipal Hospital (Group) from January 2017 to February 2018 were randomly divided into control and treatment groups, and each group had 42 cases. Patients in the control group were subcutaneous injection administered with S Recombinant Human Thrombopoietin Injection, 15 000 U/time, once daily. Patients in the treatment group were po administered with Huaiqihuang Granules on the basis of the control group, 1 bag/time, twice daily. Patients in two groups were treated for 14 d. After treatment, the clinical efficacies were evaluated, and platelet associated antibodies, platelet counts, T lymphocyte subsets in two groups were compared. Results After treatment, the clinical efficacies in the control and treatment groups were 73.81% and 90.48%, respectively, and there was difference between two groups (P<0.05). After treatment, the levels of PAIgG, PAIgA, and PAIgM in two groups were significantly decreased, but platelet counts in two groups were significantly increased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). After treatment, the levels of CD3⁺, CD4⁺, and CD4⁺/CD8⁺ in two groups were significantly increased, but the levels of CD8⁺ in two groups were significantly decreased, and the difference was statistically significant in the same group (P<0.05). And the observational indexes in the treatment group were significantly better than those in the control group, with significant difference between two groups (P<0.05). Conclusion Huaiqihuang Granules combined with recombinant human thrombopoietin has clinical curative effect in treatment of idiopathic thrombocytopenic purpura, can reduce platelet associated antibodies, improve immune function, and reduce the incidence of adverse reactions, which has a certain clinical application value.